These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32830856)

  • 1. Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.
    He Y; Li J; Koga T; Ma J; Dhawan S; Suzuki Y; Furnari F; Prabhu VV; Allen JE; Chen CC
    Neuro Oncol; 2021 Mar; 23(3):400-411. PubMed ID: 32830856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma.
    Li J; Zhu S; Kozono D; Ng K; Futalan D; Shen Y; Akers JC; Steed T; Kushwaha D; Schlabach M; Carter BS; Kwon CH; Furnari F; Cavenee W; Elledge S; Chen CC
    Oncotarget; 2014 Feb; 5(4):882-93. PubMed ID: 24658464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
    Prabhu VV; Madhukar NS; Gilvary C; Kline CLB; Oster S; El-Deiry WS; Elemento O; Doherty F; VanEngelenburg A; Durrant J; Tarapore RS; Deacon S; Charter N; Jung J; Park DM; Gilbert MR; Rusert J; Wechsler-Reya R; Arrillaga-Romany I; Batchelor TT; Wen PY; Oster W; Allen JE
    Clin Cancer Res; 2019 Apr; 25(7):2305-2313. PubMed ID: 30559168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5.
    Jeon HM; Oh YT; Shin YJ; Chang N; Kim D; Woo D; Yeup Y; Joo KM; Jo H; Yang H; Lee JK; Kang W; Sa J; Lee WJ; Hale J; Lathia JD; Purow B; Park MJ; Park JB; Nam DH; Lee J
    Neoplasia; 2023 May; 39():100894. PubMed ID: 36972629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.
    Pierce SR; Fang Z; Yin Y; West L; Asher M; Hao T; Zhang X; Tucker K; Staley A; Fan Y; Sun W; Moore DT; Xu C; Tsai YH; Parker J; Prabhu VV; Allen JE; Lee D; Zhou C; Bae-Jump V
    J Exp Clin Cancer Res; 2021 Feb; 40(1):61. PubMed ID: 33557912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
    Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
    Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
    Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY
    Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma.
    He L; Bhat K; Ioannidis A; Zhang L; Nguyen NT; Allen JE; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
    Radiother Oncol; 2021 Aug; 161():140-147. PubMed ID: 34097975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma.
    Shi L; Chen H; Chen K; Zhong C; Song C; Huang Y; Wang T; Chen L; Li C; Huang A; Qi S; Li H; Lu Y
    Clin Cancer Res; 2023 Aug; 29(16):3172-3188. PubMed ID: 37249604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells.
    Weissenrieder JS; Reed JL; Green MV; Moldovan GL; Koubek EJ; Neighbors JD; Hohl RJ
    Pharmacology; 2020; 105(1-2):19-27. PubMed ID: 31645049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
    Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells.
    Li Y; Wang W; Wang F; Wu Q; Li W; Zhong X; Tian K; Zeng T; Gao L; Liu Y; Li S; Jiang X; Du G; Zhou Y
    J Mol Cell Biol; 2017 Aug; 9(4):302-314. PubMed ID: 28486630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.
    Maisel SA; Broka D; Atwell B; Bunch T; Kupp R; Singh SK; Mehta S; Schroeder J
    J Transl Med; 2019 Jun; 17(1):201. PubMed ID: 31215437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma.
    von Achenbach C; Weller M; Szabo E
    J Neurochem; 2018 Oct; 147(1):99-109. PubMed ID: 29953622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpressed D2 Dopamine Receptor Inhibits Non-Small Cell Lung Cancer Progression through Inhibiting NF-κB Signaling Pathway.
    Wu XY; Zhang CX; Deng LC; Xiao J; Yuan X; Zhang B; Hou ZB; Sheng ZH; Sun L; Jiang QC; Zhao W
    Cell Physiol Biochem; 2018; 48(6):2258-2272. PubMed ID: 30114693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop.
    Wang Y; Wang X; Wang K; Qi J; Zhang Y; Wang X; Zhang L; Zhou Y; Gu L; Yu R; Zhou X
    J Exp Clin Cancer Res; 2023 Jul; 42(1):161. PubMed ID: 37415171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.